A new, late-stage clinical study shows disappointing results for Eli Lilly’s weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegovy, and Ozempic. (Source: Bloomberg)
www.bloomberg.com
#Eli #Lilly039s #Experimental #WeightLoss #Pill #Data #Disappoints
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
